167 related articles for article (PubMed ID: 21303982)
21. Protein Kinase RNA-Like Endoplasmic Reticulum Kinase-Mediated Bcl-2 Protein Phosphorylation Contributes to Evodiamine-Induced Apoptosis of Human Renal Cell Carcinoma Cells.
Wu WS; Chien CC; Chen YC; Chiu WT
PLoS One; 2016; 11(8):e0160484. PubMed ID: 27483435
[TBL] [Abstract][Full Text] [Related]
22. Methylation-mediated miR-214 regulates proliferation and drug sensitivity of renal cell carcinoma cells through targeting LIVIN.
Xu H; Wu S; Shen X; Shi Z; Wu D; Yuan Y; Jiang W; Wang Q; Ke Q; Mao Q; Li X; Liu Y; Yuan P; Zhang Q; Huang E; Chen X
J Cell Mol Med; 2020 Jun; 24(11):6410-6425. PubMed ID: 32395888
[TBL] [Abstract][Full Text] [Related]
23. The novel histone deacetylase inhibitor, N-hydroxy-7-(2-naphthylthio) hepatonomide, exhibits potent antitumor activity due to cytochrome-c-release-mediated apoptosis in renal cell carcinoma cells.
Park KC; Heo JH; Jeon JY; Choi HJ; Jo AR; Kim SW; Kwon HJ; Hong SJ; Han KS
BMC Cancer; 2015 Jan; 15():19. PubMed ID: 25613585
[TBL] [Abstract][Full Text] [Related]
24. 5-Aza-2'-deoxycytidine suppresses human renal carcinoma cell growth in a xenograft model via up-regulation of the connexin 32 gene.
Hagiwara H; Sato H; Ohde Y; Takano Y; Seki T; Ariga T; Hokaiwado N; Asamoto M; Shirai T; Nagashima Y; Yano T
Br J Pharmacol; 2008 Apr; 153(7):1373-81. PubMed ID: 18264126
[TBL] [Abstract][Full Text] [Related]
25. Evaluation of noncytotoxic DNMT1-depleting therapy in patients with myelodysplastic syndromes.
Saunthararajah Y; Sekeres M; Advani A; Mahfouz R; Durkin L; Radivoyevitch T; Englehaupt R; Juersivich J; Cooper K; Husseinzadeh H; Przychodzen B; Rump M; Hobson S; Earl M; Sobecks R; Dean R; Reu F; Tiu R; Hamilton B; Copelan E; Lichtin A; Hsi E; Kalaycio M; Maciejewski J
J Clin Invest; 2015 Mar; 125(3):1043-55. PubMed ID: 25621498
[TBL] [Abstract][Full Text] [Related]
26. Combined Treatment with Valproic Acid and 5-Aza-2'-Deoxycytidine Synergistically Inhibits Human Clear Cell Renal Cell Carcinoma Growth and Migration.
Xi W; Chen X; Sun J; Wang W; Huo Y; Zheng G; Wu J; Li Y; Yang A; Wang T
Med Sci Monit; 2018 Feb; 24():1034-1043. PubMed ID: 29457966
[TBL] [Abstract][Full Text] [Related]
27. Gene expression profiling of the synergy of 5-aza-2'-deoxycytidine and paclitaxel against renal cell carcinoma.
Han T; Shang D; Xu X; Tian Y
World J Surg Oncol; 2012 Sep; 10():183. PubMed ID: 22950635
[TBL] [Abstract][Full Text] [Related]
28. Higher expression of XPF is a critical factor in intrinsic chemotherapy resistance of human renal cell carcinoma.
Zhang Q; Shi J; Yuan F; Wang H; Fu W; Pan J; Huang Y; Yu J; Yang J; Chen Z
Int J Cancer; 2016 Dec; 139(12):2827-2837. PubMed ID: 27542841
[TBL] [Abstract][Full Text] [Related]
29. Effects of tetrahydrouridine on pharmacokinetics and pharmacodynamics of oral decitabine.
Lavelle D; Vaitkus K; Ling Y; Ruiz MA; Mahfouz R; Ng KP; Negrotto S; Smith N; Terse P; Engelke KJ; Covey J; Chan KK; Desimone J; Saunthararajah Y
Blood; 2012 Feb; 119(5):1240-7. PubMed ID: 22160381
[TBL] [Abstract][Full Text] [Related]
30. MiRNA-30a-mediated autophagy inhibition sensitizes renal cell carcinoma cells to sorafenib.
Zheng B; Zhu H; Gu D; Pan X; Qian L; Xue B; Yang D; Zhou J; Shan Y
Biochem Biophys Res Commun; 2015 Apr; 459(2):234-239. PubMed ID: 25712526
[TBL] [Abstract][Full Text] [Related]
31. 5-aza-2'-deoxycytidine enhances susceptibility of renal cell carcinoma to paclitaxel by decreasing LEF1/phospho-β-catenin expression.
Shang D; Liu Y; Xu X; Han T; Tian Y
Cancer Lett; 2011 Dec; 311(2):230-6. PubMed ID: 21880414
[TBL] [Abstract][Full Text] [Related]
32. Lymphocyte activation antigen CD70 expressed by renal cell carcinoma is a potential therapeutic target for anti-CD70 antibody-drug conjugates.
Law CL; Gordon KA; Toki BE; Yamane AK; Hering MA; Cerveny CG; Petroziello JM; Ryan MC; Smith L; Simon R; Sauter G; Oflazoglu E; Doronina SO; Meyer DL; Francisco JA; Carter P; Senter PD; Copland JA; Wood CG; Wahl AF
Cancer Res; 2006 Feb; 66(4):2328-37. PubMed ID: 16489038
[TBL] [Abstract][Full Text] [Related]
33. Antisense attenuation of p21 sensitizes kidney cancer to apoptosis in response to conventional DNA damaging chemotherapy associated with enhancement of phospho-p53.
Park SH; Park JY; Weiss RH
J Urol; 2008 Jul; 180(1):352-60. PubMed ID: 18499163
[TBL] [Abstract][Full Text] [Related]
34. The failure of DAC to induce OCT2 expression and its remission by hemoglobin-based nanocarriers under hypoxia in renal cell carcinoma.
Chen L; Wang Z; Xu Q; Liu Y; Chen L; Guo S; Wang H; Zeng K; Liu J; Zeng S; Yu L
Theranostics; 2020; 10(8):3562-3578. PubMed ID: 32206108
[No Abstract] [Full Text] [Related]
35. Gramicidin A induces metabolic dysfunction and energy depletion leading to cell death in renal cell carcinoma cells.
David JM; Owens TA; Barwe SP; Rajasekaran AK
Mol Cancer Ther; 2013 Nov; 12(11):2296-307. PubMed ID: 24006494
[TBL] [Abstract][Full Text] [Related]
36. PPARα inhibition modulates multiple reprogrammed metabolic pathways in kidney cancer and attenuates tumor growth.
Abu Aboud O; Donohoe D; Bultman S; Fitch M; Riiff T; Hellerstein M; Weiss RH
Am J Physiol Cell Physiol; 2015 Jun; 308(11):C890-8. PubMed ID: 25810260
[TBL] [Abstract][Full Text] [Related]
37. 5-Aza-2'-Deoxycytidine and CDDP Synergistically Induce Apoptosis in Renal Carcinoma Cells via Enhancing the APAF-1 Activity.
Zhu X; Yi F; Chen P; Chen L; Zhang X; Cao C; Tan W
Clin Lab; 2015; 61(12):1821-30. PubMed ID: 26882803
[TBL] [Abstract][Full Text] [Related]
38. Triptolide enhances the tumoricidal activity of TRAIL against renal cell carcinoma.
Brincks EL; Kucaba TA; James BR; Murphy KA; Schwertfeger KL; Sangwan V; Banerjee S; Saluja AK; Griffith TS
FEBS J; 2015 Dec; 282(24):4747-4765. PubMed ID: 26426449
[TBL] [Abstract][Full Text] [Related]
39. Harnessing the p53-PUMA axis to overcome DNA damage resistance in renal cell carcinoma.
Zhou X; Tolstov Y; Arslan A; Roth W; Grüllich C; Pahernik S; Hohenfellner M; Duensing S
Neoplasia; 2014 Dec; 16(12):1028-35. PubMed ID: 25499216
[TBL] [Abstract][Full Text] [Related]
40. Scutellarin inhibits human renal cancer cell proliferation and migration via upregulation of PTEN.
Deng W; Han W; Fan T; Wang X; Cheng Z; Wan B; Chen J
Biomed Pharmacother; 2018 Nov; 107():1505-1513. PubMed ID: 30257368
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]